Relatedly, in breast and colon tumor models, anti-PD-1 or anti-CTLA-4 treatment boosted vessel perfusion through the promotion of CD8+ T-cell accumulation and IFN-γ production, suggesting that improved vessel perfusion was contingent on upregulated T-cell immunity induced by checkpoint blockade (79). This evidence concerns the gene CTLA4 and colonic neoplasm.